| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/28/2010 | US20100021555 Compositions containing high omega-3 and low saturated fatty acid levels |
| 01/28/2010 | US20100021544 Hydrogel and biomedical applications thereof |
| 01/28/2010 | US20100021524 Pimethixene derivatives for promoting bone growth |
| 01/28/2010 | US20100021519 Compositions and Methods for Treating or Preventing Diseases of Body Passageways |
| 01/28/2010 | US20100021500 Processes for treating subjects carrying viral infectious agent |
| 01/28/2010 | US20100021493 Extracts of aphanizomenon flos aquae and nutritional, cosmetic and pharmaceutical compositons containing the same |
| 01/28/2010 | US20100021482 Novel death associated proteins, and thap1 and par4 pathways in apoptosis control |
| 01/28/2010 | US20100021480 Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same |
| 01/28/2010 | US20100021479 Monoclonal Antibodies Against CD30 Lacking in Fucosyl Residues |
| 01/28/2010 | US20100021475 Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
| 01/28/2010 | US20100021474 Methods and compositions for targeting hepsin |
| 01/28/2010 | US20100021473 Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor |
| 01/28/2010 | US20100021471 Carbon nanotube-based drug delivery systems and methods of making same |
| 01/28/2010 | US20100021469 Functional role of adrenomedullin (am) and the gene related product (pamp) in human pathology and physiology |
| 01/28/2010 | US20100021468 Novel mhc class ii restricted t cell epitopes from the cancer anitgen, ny eso-1 |
| 01/28/2010 | US20100021467 Method of detecting a cancer cell by aberrant expression of a human k+ ion channel |
| 01/28/2010 | US20100021459 Polypeptide constructs for intracellular delivery |
| 01/28/2010 | US20100021442 Method for promoting immunotherapy using an agent for elevating dendritic cell precursor level in blood |
| 01/28/2010 | US20100021441 Mhc molecule-binding tumor-associated peptides |
| 01/28/2010 | US20100021438 Kidney derived stem cells and methods for their isolation, differentiation and use |
| 01/28/2010 | US20100021432 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus |
| 01/28/2010 | US20100021424 Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy |
| 01/28/2010 | US20100021394 High penetration prodrug compositions of 1h-imidazo[4,5-c]quinolin-4-amines and 1h-imidazo[4,5-c]quinolin-4-amine-related compounds |
| 01/28/2010 | US20100021387 Methods for Inducing Reversible Stasis |
| 01/28/2010 | DE102008035442A1 Zubereitungen aus Artemisia Annua, ihre Umwandlung in Mikro- und Nanopartikel und ihre Verwendung Preparations from Artemisia annua, their conversion into micro- and nanoparticles and their use |
| 01/28/2010 | CA2736842A1 Proteins for use in diagnosing and treating infection and disease |
| 01/28/2010 | CA2731938A1 Solid pharmaceutical composition comprising exemestane |
| 01/28/2010 | CA2731789A1 Alkyl thiazole carbamate derivatives, preparation thereof, and use thereof as faah enzyme inhibitors |
| 01/28/2010 | CA2731781A1 Methods for the cytological analysis of cervical cells |
| 01/28/2010 | CA2731773A1 Amidophenoxyindazoles useful as inhibitors of c-met |
| 01/28/2010 | CA2731730A1 Deacetylase inhibitors and uses thereof |
| 01/28/2010 | CA2731501A1 Transdermal pharmaceutical compositions comprising danazol |
| 01/28/2010 | CA2731498A1 Tri-cyclic pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731496A1 Pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731451A1 Pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731432A1 Tri-cyclic pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731146A1 3,4-diarylpyrazoles as protein kinase inhibitors |
| 01/28/2010 | CA2728932A1 Pyrrolobenzodiazepines |
| 01/28/2010 | CA2690828A1 Composition containing microrna-21 inhibitor for enhancing radiation sensitivity |
| 01/27/2010 | EP2147978A2 N-Terminally truncated HER-2/NEU protein as a cancer prognostic indicator |
| 01/27/2010 | EP2147926A1 Truncated human papillomavirus type 18 l1 proteins |
| 01/27/2010 | EP2147922A1 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| 01/27/2010 | EP2147683A1 Construct and method for the internalization of cargo molecules into a cell |
| 01/27/2010 | EP2147682A2 Vaccination with immuno-isolated cells producing an immunomodulator |
| 01/27/2010 | EP2147679A2 Compositions and methods for modulating blood-brain barrier transport |
| 01/27/2010 | EP2147674A1 Transdermal pharmaceutical compositions comprising danazol |
| 01/27/2010 | EP2147673A1 Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| 01/27/2010 | EP2147672A1 Cytotoxic t cell activator comprising ep4 agonist |
| 01/27/2010 | EP2147670A1 Chemically stable compositions of 4-hydroxy tamoxifen |
| 01/27/2010 | EP2147122A1 Enzymatic anticancer therapy |
| 01/27/2010 | EP2147005A1 Metal triangulo compound and methods of using the same |
| 01/27/2010 | EP2146991A2 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 01/27/2010 | EP2146988A1 New 4,8-diphenyl-polyazanaphthalene derivatives |
| 01/27/2010 | EP2146986A1 Diphenyl-dihydro-imidazopyridinones |
| 01/27/2010 | EP2146982A2 Aminopyrimidines useful as kinase inhibitors |
| 01/27/2010 | EP2146967A2 Tetrahydroindole and tetrahydroindazole derivatives |
| 01/27/2010 | EP2146779A1 Sulfonyl amide derivatives for the treatment of abnormal cell growth |
| 01/27/2010 | EP2146740A1 Methods of controlling tumorigenesis and diagnosing the risk thereof |
| 01/27/2010 | EP2146736A2 Modulators of vegf splicing as pro- and anti-angiogenic agents |
| 01/27/2010 | EP2146735A1 Sparc and methods of use thereof |
| 01/27/2010 | EP2146731A1 New use for cannabinoid-containing plant extracts |
| 01/27/2010 | EP2146726A1 Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| 01/27/2010 | EP2146718A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| 01/27/2010 | EP2146717A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| 01/27/2010 | EP2146716A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| 01/27/2010 | EP2146710A1 P38alpha as a therapeutic target in bladder carcinoma |
| 01/27/2010 | EP2146709A2 Iminosugar for treatment of tumors |
| 01/27/2010 | EP2146632A1 Compositions and methods for cellular imaging and therapy |
| 01/27/2010 | EP1732574B1 Use of o-atp for the treatment of diseases involving angiogenesis |
| 01/27/2010 | EP1711461B1 N-deacetylthiocolchicine derivatives, their use and pharmaceutical formulations containing them |
| 01/27/2010 | EP1562612B1 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine for use in the treatment or prophlaxix of pancreatic cancer |
| 01/27/2010 | EP1438298B1 Piperazine derivatives with ccr1 receptor antagonist activity |
| 01/27/2010 | EP1343485B1 Drug delivery system comprising a lipid-based nitric oxide donor |
| 01/27/2010 | EP1303503B1 Aniline derivatives |
| 01/27/2010 | EP1206563B1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 01/27/2010 | CN101633907A Amplification culture method for antigen specific cytotoxic t lymphocytes |
| 01/27/2010 | CN101633692A Methods for making apo-2 ligand using divalent metal ions |
| 01/27/2010 | CN101633650A Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 01/27/2010 | CN101633645A N3 alkylated benzimidazole derivatives as mek inhibitors |
| 01/27/2010 | CN101633644A N3 alkylated benzimidazole derivatives as mek inhibitors |
| 01/27/2010 | CN100584945C Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression |
| 01/27/2010 | CN100584856C Hedera helix saponin, preparation method and antineoplastic use thereof |
| 01/27/2010 | CN100584841C Andrographolide derivatives and application of the same in pharmacy |
| 01/27/2010 | CN100584840C Substituted heterocyclic compounds and uses thereof |
| 01/27/2010 | CN100584838C Eremophilone lactones acid natural product and application thereof |
| 01/27/2010 | CN100584819C Substituted 4-aminocyclohexanol derivatives |
| 01/27/2010 | CN100584370C Traditional Chinese medicine for treating digestive cancer |
| 01/27/2010 | CN100584363C Traditional Chinese medicine oral liquid for treating damnification of immunity function after chemotherapy of cancer of the esophagus cancer patient |
| 01/27/2010 | CN100584352C Application of Chinese magnoliaving and its extractive on curing drug resistance for multiple drugs of treating tumors |
| 01/27/2010 | CN100584351C Anticancer medicine and its preparation |
| 01/27/2010 | CN100584349C Chinese traditional western compound medicine and its preparation method |
| 01/27/2010 | CN100584343C Medicine health-care usage of globefish I collagen extraction and preparing process thereof |
| 01/27/2010 | CN100584336C Medicinal compositions |
| 01/27/2010 | CN100584317C Traditional Chinese medicine compound preparation for preventing gastric cancer metastasis and preparation method thereof |
| 01/26/2010 | US7652155 Diamine derivative, production process therefor and antioxidant |
| 01/26/2010 | US7652144 Compounds as PDE IV and TNF inhibitors |
| 01/26/2010 | US7652135 Compositions useful as inhibitors of protein kinases |
| 01/26/2010 | US7652054 Gastrointestinal disorders; cardiovascular disorders; dyspepsia;anticancer agents; antiulcer agents |
| 01/26/2010 | US7652051 3-amino-benzo[1,2,4]triazine-7-ol-1-oxide; 4-[3-(4-chloro-phenylamino)-benzo[1,2,4]triazin-7-yloxy]-pyridine-2-carboxylic acid methylamide trifluoroacetate salt; modulation of the MAPK pathway; cancer |
| 01/26/2010 | US7652045 Activator of peroxisome proliferator-activated receptor δ |